Individualization and personalization of high-priced drug therapies for safer, predictable and more effective treatment outcomes continue to be the growth drivers in the companion diagnostics segment. Newer, automated technologies have transformed the way physicians detect and diagnose cancers and genetic diseases at an early stage. This has also paved the way for personalized medicine, which can identify the predisposition of a patient, disease based on genetic variants, and target therapy at the right time.
We collaborate with diagnostic labs and partners to provide access to innovative molecular companion diagnostic products aimed at transforming patient care. South Asia is showing considerable growth in the next-generation diagnostics innovations due to increasing prevalence of cancers and musculoskeletal diseases, increasing disposable incomes for quality care, and improving healthcare infrastructure.
Sayre will plan on offering CDx as a bundled service with our novel medicines portfolio, where applicable.